According to a study published on Wednesday, a third dose of either Pfizer-BioNTech's or Moderna's COVID-19 vaccine is likely to increase the protection against the Omicron variant in the elderly.
The study, which isn't yet peer-reviewed, examined the effect of COVID-19 vaccines using mRNA techniques against the Delta and the new, more infectious Omicron variant.
"Our study is on the basis of advanced evidence that BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) primary vaccine protection against Omicron increases quickly over time, with the booster vaccination giving an important increase in protection," wrote the authors.
The study was conducted by researchers at the leading infectious disease authority in Denmark, Statens Serum Institut (SSI). It analysed three million Danes collected between Nov. 20 and Dec. 12.
Cheer people are among the two who recently had their second vaccine dose. In comparison, effectiveness against Omicron was measured at 55.2% for Pfizer-BioNTech and 36.7% for Moderna.
The researchers said the protection quickly declined over the course of five months.
In spite of the antibiotic hazard, the body of studies finds the effects of the infection reduced on our ears to low. We have been doing more research in the field of bacterial diseases, according to the authors.
If only two doses of the vaccine were enough, protection by three-fold in adults aged 60 and older who had been inoculated 14 to 44 days earlier, increased to 54,6% in the same period as those with only two doses.
The study confirms the findings from a recent British study, which also showed a rapid decline over time and an increased proportion of products produced in the vaccine booster.
According to the exponential rise in Omicron cases, these findings highlight the need for massive implementation of vaccines and booster vaccinations, according to the researchers.